Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results from a French Cohort-Reference-Cited by-同舟云学术

Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results from a French Cohort

Published:2015-04 Issue:4 Volume:25 Page:386-391
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Chougnet Cecile N.¹²,Borget Isabelle³,Leboulleux Sophie²,de la Fouchardiere Christelle⁴,Bonichon Françoise⁵,Criniere Lise⁶,Niccoli Patricia⁷,Bardet Stéphane⁸,Schneegans Olivier⁹,Zanetta Sylvie¹⁰,Schvartz Claire¹¹,Drui Delphine¹²,Chauffert Bruno¹³,Rohmer Vincent¹⁴,Schlumberger Martin²

Affiliation:

1. Department of Nuclear Medicine, Hôpital Saint Louis, Paris, France.

2. Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Villejuif, France.

3. Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France.

4. Department of Oncology, Centre Leon Berard, Lyon, France.

5. Department of Nuclear Medicine, Institut Bergonié, Bordeaux, France.

6. Department of Endocrinology, CHU Tours, Tours, France.

7. Department of Medical Oncology, Institut Paoli Calmette, Marseille, France.

8. Department of Nuclear Medicine and Thyroid Unit, Centre François Baclesse, Caen, France.

9. Department of Nuclear Medicine, Centre Paul Strauss, Strasbourg, France.

10. Department of Oncology, Centre Francois Leclerc, Dijon, France.

11. Department of Nuclear Medicine, Institut Godinot, Reims, France.